immunogen is a clinical-stage biotechnology company that develops targeted anticancer therapeutics with its proprietary antibody-drug conjugate (adc) technology. the company's lead product candidate, mirvetuximab soravtansine, is a potential treatment for folate receptor α-positive ovarian cancers and other solid tumors. leading healthcare companies have licensed rights to use immunogen's technology to develop novel anticancer therapies, and roche's marketed product, kadcyla, utilizes immunogen's adc technology. more information about the company can be found at www.immunogen.com.
Company profile
Ticker
IMGN
Exchange
Website
CEO
Mark Enyedy
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
IMMUNOGEN INC
SEC CIK
Corporate docs
Subsidiaries
Hurricane, LLC • ImmunoGen US Holding, Inc. • ImmunoGen Europe Limited • ImmunoGen Switzerland GmbH • ImmunoGen BioPharma (Ireland) Limited • ImmunoGen Securities Corp. ...
IRS number
42726691
IMGN stock data
Latest filings (excl ownership)
15-12G
Securities registration termination
22 Feb 24
S-8 POS
Registration of securities for employees (post-effective amendment)
12 Feb 24
S-8 POS
Registration of securities for employees (post-effective amendment)
12 Feb 24
S-8 POS
Registration of securities for employees (post-effective amendment)
12 Feb 24
S-8 POS
Registration of securities for employees (post-effective amendment)
12 Feb 24
S-8 POS
Registration of securities for employees (post-effective amendment)
12 Feb 24
S-8 POS
Registration of securities for employees (post-effective amendment)
12 Feb 24
S-8 POS
Registration of securities for employees (post-effective amendment)
12 Feb 24
S-8 POS
Registration of securities for employees (post-effective amendment)
12 Feb 24
S-8 POS
Registration of securities for employees (post-effective amendment)
12 Feb 24
Transcripts
IMGN
Earnings call transcript
2023 Q3
2 Nov 23
IMGN
Earnings call transcript
2023 Q2
31 Jul 23
IMGN
Earnings call transcript
2023 Q1
28 Apr 23
IMGN
Earnings call transcript
2022 Q4
1 Mar 23
IMGN
Earnings call transcript
2022 Q3
4 Nov 22
IMGN
Earnings call transcript
2022 Q2
29 Jul 22
IMGN
Earnings call transcript
2022 Q1
6 May 22
IMGN
Earnings call transcript
2021 Q4
25 Feb 22
IMGN
Earnings call transcript
2021 Q3
29 Oct 21
IMGN
Earnings call transcript
2021 Q2
30 Jul 21
Latest ownership filings
SC 13G/A
RA CAPITAL MANAGEMENT, L.P.
14 Feb 24
SC 13G/A
Redmile Group, LLC
14 Feb 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
4
DEAN J MITCHELL
12 Feb 24
4
Kristine Peterson
12 Feb 24
4
Helen M. Thackray
12 Feb 24
4
Mark J Enyedy
12 Feb 24
4
Richard John Wallace
12 Feb 24
4
Stacy Ann Coen
12 Feb 24
4
Renee Lentini
12 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 605.54 mm | 605.54 mm | 605.54 mm | 605.54 mm | 605.54 mm | 605.54 mm |
Cash burn (monthly) | (no burn) | (no burn) | (no burn) | 6.38 mm | (no burn) | 16.49 mm |
Cash used (since last report) | n/a | n/a | n/a | 43.65 mm | n/a | 112.83 mm |
Cash remaining | n/a | n/a | n/a | 561.88 mm | n/a | 492.71 mm |
Runway (months of cash) | n/a | n/a | n/a | 88.1 | n/a | 29.9 |
Institutional ownership, Q4 2023
55.9% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 233 |
Opened positions | 83 |
Closed positions | 121 |
Increased positions | 48 |
Reduced positions | 76 |
13F shares | Current |
---|---|
Total value | 4.04 tn |
Total shares | 148.89 mm |
Total puts | 1.18 mm |
Total calls | 1.55 mm |
Total put/call ratio | 0.8 |
Largest owners | Shares | Value |
---|---|---|
Vanguard | 25.47 mm | $755.10 bn |
Ra Capital Management | 23.75 mm | $704.21 bn |
STT State Street | 8.08 mm | $239.44 bn |
Flynn James E | 6.36 mm | $0.00 |
Fairmount Funds Management | 5.93 mm | $175.81 bn |
FIL | 5.36 mm | $158.92 bn |
MS Morgan Stanley | 4.11 mm | $121.84 bn |
Maverick Capital | 2.49 mm | $73.92 bn |
NTRS Northern Trust | 2.33 mm | $69.05 bn |
TIG Advisors | 2.31 mm | $68.60 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
12 Feb 24 | Lauren White | RSU Common Stock | Sale back to company | Acquire D | No | No | 0 | 19,519 | 0.00 | 0 |
12 Feb 24 | Lauren White | RSU Common Stock | Sale back to company | Acquire D | No | No | 0 | 51,625 | 0.00 | 0 |
12 Feb 24 | Lauren White | Stock Option Common Stock | Sale back to company | Acquire D | No | No | 15.71 | 295,975 | 4.65 mm | 0 |
12 Feb 24 | Daniel Char | Common Stock | Sale back to company | Dispose D | No | No | 0 | 1,000 | 0.00 | 0 |
12 Feb 24 | Daniel Char | RSU Common Stock | Sale back to company | Dispose D | No | No | 0 | 22,825 | 0.00 | 0 |
12 Feb 24 | Daniel Char | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 5.19 | 400,000 | 2.08 mm | 0 |
12 Feb 24 | Michael Vasconcelles | Common Stock | Sale back to company | Dispose D | No | No | 0 | 1,327 | 0.00 | 0 |
12 Feb 24 | Michael Vasconcelles | RSU Common Stock | Sale back to company | Dispose D | No | No | 0 | 50,515 | 0.00 | 0 |
12 Feb 24 | Michael Vasconcelles | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 5.16 | 960,000 | 4.95 mm | 0 |
12 Feb 24 | Tracey L McCain | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 5.68 | 44,000 | 249.92 k | 0 |